PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2023
Filed with the SEC on Mar 16, 2023 and accepted by EDGAR at Mar 16, 2023, 20:42 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-11-01 to 2023-01-31 | $0 | us-gaap:Revenues |
| Revenue | 9 months2022-05-01 to 2023-01-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2022-11-01 to 2023-01-31 | $45.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-05-01 to 2023-01-31 | $382.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-11-01 to 2023-01-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-05-01 to 2023-01-31 | −$5.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-11-01 to 2023-01-31 | $0 | us-gaap:InterestExpense |
| Interest expense | 9 months2022-05-01 to 2023-01-31 | $0 | us-gaap:InterestExpense |
| Net income | 3 months2022-11-01 to 2023-01-31 | −$764.1k | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-05-01 to 2023-01-31 | −$4.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-11-01 to 2023-01-31 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-05-01 to 2023-01-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-11-01 to 2023-01-31 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-05-01 to 2023-01-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-11-01 to 2023-01-31 | 18,995,442 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-05-01 to 2023-01-31 | 20,051,617 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-05-01 to 2023-01-31 | −$3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months2022-05-01 to 2023-01-31 | $9.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-01-31 | $72.6m | us-gaap:Cash |
| Current assets | At period end2023-01-31 | $72.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-01-31 | $78.0m | us-gaap:Assets |
| Current liabilities | At period end2023-01-31 | $827.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-01-31 | $827.8k | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-01-31 | $77.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-23-001559. Last ingested by Listed: Oct 24, 2026, 15:05 ET. Listed shows no prices and gives no investment advice.